Rift valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6161-6171

  Dodd, Kimberly A ^a,b   McElroy, Anita K ^a,c   Jones, Megan E B ^a,d   Nichol, Stuart T ^a   Spiropoulou, Christina F ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; AFRICA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; T CELL DEPLETION; T LYMPHOCYTE; VIRAL CLEARANCE; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; NERVOUS SYSTEM DISEASES; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84878170869     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00337-13     Document Type: Article

References (46)

1. Chevalier V, Pépin M, Plée L, Lancelot R. 2010. Rift Valley fever-a threat for Europe? Euro Surveill. 15:19506. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19506.
2. Elliott RM. 2009. Bunyaviruses and climate change. Clin. Microbiol. Infect. 15:510 -517.
3. Turell MJ, Wilson WC, Bennett KE. 2010. Potential for North American mosquitoes (Diptera: Culicidae) to transmit Rift Valley fever virus. J. Med. Entomol. 47:884-889.
4. Swanepoel R, Paweska JT. 2011. Rift Valley fever, p 423-431. In Palmer S, Soulsby L, Torgerson P, Brown DWG (ed), Oxford textbook of zoonoses: biology, clinical practice, and public health, 2nd ed. Oxford University Press, New York, NY.
5. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. 2009. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234:883- 893.
6. Bird BH, Albariño CG, Nichol ST. 2007. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362:10 -15.
7. Vialat P, Billecocq A, Kohl A, Bouloy M. 2000. The S segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J. Virol. 74:1538 -1543.
8. Bird BH, Albariño CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. 2008. Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82:2681-2691.
9. Won S, Ikegami T, Peters CJ, Makino S. 2007. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81:13335-13345.
10. Terasaki K, Won S, Makino S. 2013. The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts antiapoptotic function. J. Virol. 87:676-682.
11. Crabtree MB, Kent Crockett RJ, Bird BH, Nichol ST, Erickson BR, Biggerstaff BJ, Horiuchi K, Miller BR. 2012. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl. Trop. Dis. 6:e1639. doi:10.1371/journal.pntd.0001639.
12. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, Huerre M, Haller O. 2001. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J. Virol. 75:1371-1377.
13. Billecocq A, Spiegel M, Vialat P, Kohl A, Weber F, Bouloy M, Haller O. 2004. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78:9798 -9806.
14. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, Egly J-M. 2004. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116:541-550.
15. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, Superti-Furga G, Unger H, Weber F. 2009. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNAdependent protein kinase. J. Virol. 83:4365- 4375.
16. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. 2009. Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E75-E85.
17. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, Billecocq A, Flick R, Jacob Y, Bonnefoy E, Bouloy M. 2008. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 4:e13. doi:10.1371/journal.ppat.0040013.
18. Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B, McElroy AK, Khristova ML, Albariño CG, Nichol ST. 2011. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85:12901-12909.
19. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, Smith J, Bouloy M. 1995. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53:405- 411.
20. Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albariño CG. 2012. Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. J. Virol. 86:4204- 4212.
21. Morrill JC, Peters CJ. 2011. Mucosal immunization of rhesus macaques with Rift Valley fever MP-12 vaccine. J. Infect. Dis. 204:617- 625.
22. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M. 2010. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine 28:4581- 4587.
23. Kortekaas J, Oreshkova N, Cobos-Jiménez V, Vloet RPM, Potgieter CA, Moormann RJM. 2011. Creation of a non-spreading Rift Valley fever virus. J. Virol. 85:12622-12630.
24. Peters CJ, Jones D, Trotter R, Donaldson J, White J, Stephen E, Slone TW. 1988. Experimental Rift Valley fever in rhesus macaques. Arch. Virol. 99:31- 44.
25. Bhardwaj N, Heise MT, Ross TM. 2010. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis. 4:e725. doi:10.1371/journal.pntd.0000725.
26. Gray KK, Worthy MN, Juelich TL, Agar SL, Poussard A, Ragland D, Freiberg AN, Holbrook MR. 2012. Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse. PLoS Negl. Trop. Dis. 6:e1529. doi:10.1371/journal.pntd.0001529.
27. McElroy AK, Albariño CG, Nichol ST. 2009. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol. J. 6:125. doi:10.1186/1743-422X-6-125.
28. Bird BH, Bawiec DA, Ksiazek TG, Shoemaker TR, Nichol ST. 2007. Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus. J. Clin. Microbiol. 45:3506 -3513.
29. McElroy AK, Nichol ST. 2012. Rift Valley fever virus inhibits a proinflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 422:6 -12.
30. Anderson GW, Peters CJ. 1988. Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb. Pathog. 5:241-250.
31. Morrill JC, Jennings GB, Johnson AJ, Cosgriff TM, Gibbs PH, Peters CJ. 1990. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 110:195-212.
32. Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ. 1989. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev. of Infect. Dis. 11(Suppl. 4):S815-S825.
33. Gommet C, Billecocq A, Jouvion G, Hasan M, Zaverucha Do Valle T, Guillemot L, Blanchet C, Van Rooijen N, Montagutelli X, Bouloy M, Panthier J-J. 2011. Tissue tropism and target cells of NSs-deleted Rift Valley fever virus in live immunodeficient mice. PLoS Negl. Trop. Dis. 5:e1421. doi:10.1371/journal.pntd.0001421.
34. + T cells in immunity to viruses. Nat. Rev. Immunol. 12:136 -148.
35. + T-cell responses are required for clearance of West Nile virus from the central nervous system. J. Virol. 80:12060 -12069.
36. +T cell responses. Virology 411:216 -228.
37. Lund JM, Hsing L, Pham TT, Rudensky AY. 2008. Coordination of early protective immunity to viral infection by regulatory T cells. Science 320: 1220-1224.
38. +depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin. Cancer Res. 15:6881- 6890.
39. + T-cells. PLoS One 6:e20472. doi:10.1371/journal.pone.0020472.
40. Schäfer A, Brooke CB, Whitmore AC, Johnston RE. 2011. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J. Virol. 85:10682-10690.
41. Wang P, Bai F, Zenewicz LA, Dai J, Gate D, Cheng G, Yang L, Qian F, Yuan X, Montgomery RR, Flavell RA, Town T, Fikrig E. 2012. IL-22 signaling contributes to West Nile encephalitis pathogenesis. PLoS One 7:e44153. doi:10.1371/journal.pone.0044153.
42. Roe K, Kumar M, Lum S, Orillo B, Nerurkar VR, Verma S. 2012. West Nile virus-induced disruption of the blood-brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J. Gen. Virol. 93:1193-1203.
43. +T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185:5405-5416.
44. + T cells in control of West Nile virus infection. J. Virol. 78:8312- 8321.
45. + T cells to recovery from infection in a murine model of Japanese encephalitis. J. Virol. 85:5446 -5455.
46. Brooke CB, Deming DJ, Whitmore AC, White LJ, Johnston RE. 2010. T cells facilitate recovery from Venezuelan equine encephalitis virusinduced encephalomyelitis in the absence of antibody. J. Virol. 84:4556- 4568.